, 3 Direction of Research and Innovation, Centre Oscar Lambret, 3 rue Combemale, 59020 Lille cedex, France. 4 Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France. 5 Department of Medical Oncology, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94800 Villejuif, France. 6 Department of Medical Oncology, Centre René Gauducheau, 13009.

, 11 Department of Clinical Research and Innovation, p.59020

F. Lille,

N. Penel, S. Marreaud, Y. M. Robin, and P. Hohenberger, Angiosarcoma: state of the art and perspectives, Crit Rev Oncol Hematol, vol.80, pp.257-63, 2011.

N. Penel, A. Italiano, I. Ray-coquard, L. Chaigneau, C. Delcambre et al., Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome, Ann Oncol, vol.23, pp.517-540, 2012.

E. The, European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.102-114, 2014.

W. Tokuyama, T. Mikami, M. Masuzawa, and I. Okayasu, Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face, Hum Pathol, vol.41, pp.407-421, 2010.

J. R. Hasenstein, K. Kasmerchak, D. Buehler, G. R. Hafez, K. Cleary et al., Efficacy of Tie2 receptor antagonism in angiosarcoma, Neoplasia, vol.14, pp.131-171, 2012.

E. Itakura, H. Yamamoto, Y. Oda, and M. Tsuneyoshi, Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas, J Surg Oncol, vol.97, pp.74-81, 2008.

C. Zietz, M. Rossle, C. Haas, A. Sendelhofert, A. Hirschmann et al., MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF upregulation in angiosarcomas, Am J Pathol, vol.153, pp.1425-1458, 1998.

A. L. Folpe, T. Veikkola, R. Valtola, and S. W. Weiss, Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas, Mod Pathol, vol.13, pp.180-185, 2000.

C. R. Antonescu, A. Yoshida, T. Guo, N. E. Chang, L. Zhang et al., KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors, Cancer Res, vol.69, pp.7175-7184, 2009.

J. L. Arbiser, H. Larsson, L. Claesson-welsh, X. Bai, K. Lamontagne et al., Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo, American J Pathol, vol.156, pp.1469-76, 2000.

L. F. Brown, B. J. Dezube, K. Tognazzi, H. F. Dvorak, and G. D. Yancopoulos, Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma, American J Pathol, vol.156, pp.2179-83, 2000.

E. Stacher, U. Gruber-mosenbacher, I. Halbwedl, D. Tos, A. P. Cavazza et al., The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets? Lung Cancer, vol.65, pp.49-55, 2009.

S. Behjati, P. S. Tarpey, H. Sheldon, I. Martincorena, P. Van-loo et al., Recurrent PTPRB and PLCG1 mutations in angiosarcoma, Nat Genet, vol.46, pp.376-385, 2014.

I. Ray-coquard, J. Domont, E. Tresch-bruneel, E. Bompas, P. A. Cassier et al., Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial, J Clin Oncol, vol.33, pp.2797-802, 2015.

N. Penel, I. Ray-coquard, V. Bal-mahieu, C. Chevreau, L. Cesne et al., Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from phase II trial, Target Oncol, vol.9, pp.273-280, 2014.

M. Agulnik, J. L. Yarber, S. H. Okuno, M. Von-mehren, B. D. Jovanovic et al., An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas, Ann Oncol, vol.24, pp.257-63, 2013.

D. Angelo, S. P. Mahoney, M. R. Van-tine, B. A. Adkins, D. R. Perdekamp et al., Alliance A091103 a phase II study of the angiopoietin, vol.1

, peptibody trebananib for the treatment of angiosarcoma, Cancer Chemother Pharmacol, vol.75, pp.629-667, 2015.

S. Attia, K. K. Sankhala, R. F. Riedel, S. I. Robinson, R. M. Conry et al., A phase 1B/ phase 2A study of TRC105 (Endoglin antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissuesarcoma (STS)

, J Clin Oncol, vol.34, p.11016, 2016.

A. Italiano, A. Cioffi, N. Penel, M. G. Levra, C. Delcambre et al., Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas, Cancer, vol.118, pp.3330-3336, 2012.

S. Sleijfer, T. Gorlia, C. Lamers, H. Burger, J. Y. Blay et al., Cytokine and angiogenic factors associated with efficacy and toxicity in advanced soft tissue sarcomA: an EORTC STBSG study, Br J Cancer, vol.107, pp.659-704, 2012.

A. Martinetti, R. Miceli, E. Sottotetti, D. Bartolomeo, M. De-braud et al., Circulating biomarkers in advanced colorectal patients randomly assigned to three bevacizumab-based regimens, Cancer, vol.6, pp.1753-68, 2014.

V. Boige, D. Malka, A. Bourredjem, C. Dromain, C. Baey et al., Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma, Oncologist, vol.17, pp.1063-72, 2012.

Y. E. Kim, B. Joo, M. S. Park, S. J. Shin, J. B. Ahn et al., Dynamic contrastenhanced magnetic resonance imaging as a surrogate biomarker for bevacizumab in colorectal cancer liver metastasis: a single-arm exploratory trial, Cancer Res Treat, vol.48, pp.1210-1231, 2016.

R. S. Heist, D. G. Duda, D. V. Sahani, M. Ancukiewicz, P. Fidias et al., Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proc Natl Acad Sci U S A, vol.112, pp.1547-52, 2015.

F. Loupakis, V. Cremolini, A. Fioravanti, P. Orlandi, L. Salvatore et al., Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevaciazumab schedule in metastatic colorectal cancer, Br J Cancer, vol.104, pp.1262-1271, 2011.

S. Kopetz, P. M. Hoff, J. S. Morris, R. A. Wolff, C. Eng et al., Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance, J Clin Oncol, vol.28, pp.453-462, 2010.